The Law Offices of Frank R. Cruz announces an investigation on behalf of Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN) investors concerning the Company and its officers’ possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On March 27, 2018, STAT published a report revealing that the Company’s recent stock performance was due to “flimsy” claims in connection to the efficacy of imetelstat, Geron’s experimental myelofibrosis treatment. STAT stated that the available data for imetelstat undercuts Geron’s representations as to the drug’s efficacy.
On this news, Geron’s share price fell $1.75, or over 29%, over two consecutive trading sessions to close at $4.23 per share on March 27, 2018, thereby injuring investors.
Then, on September 27, 2018, Geron disclosed its Phase 2 study results for imetelstat failed to meet its primary efficacy endpoints.
On this news, Geron’s share price fell $3.92, or over 62%, to close at $2.31 per share on September 27, 2018, thereby injuring investors further.
Follow us for updates on Twitter: twitter.com/FRC_LAW.
If you purchased Geron securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to firstname.lastname@example.org, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.